For UK pharmaceutical and life sciences leaders
You know the private prescribing market exists, you have no plan to reach it
The UK private healthcare market is worth billions and growing, yet it operates by entirely different rules to the NHS. Without a dedicated approach, that revenue simply accrues to competitors who moved first.
Two minutes. Solva follows up with specific private market access options.
- Limited product availability in private pharmacies or hospital formularies
- Private prescribers being unaware of the product or its benefits
- Patients struggling to access privately prescribed medication
- Missed revenue opportunities from self-pay and privately insured patients
- Inefficient resource allocation focused solely on NHS channels
- Delayed patient access to innovative treatments in the private sector
- Loss of potential revenue from a growing private market
- Reduced return on investment for R&D in products with private market potential
- Perception of the company as slow to adapt to market changes
- Missed opportunities to improve patient outcomes in the private sector
No verified UK data available for specific private prescribing volume growth or impact of structured market access strategies as stated in the problem card. However, the UK private healthcare market is growing, driven by increased self-pay and private medical insurance admissions (PHIN, 2026; LaingBuisson, 2025).
Frequently asked questions
Why does this problem persist?
The UK private prescribing market is structurally different from the NHS market and requires a distinct commercial approach. Private prescribers including consultants, GPs, and private clinics operate outside NHS formulary constraints and can prescribe licensed medicines based on clinical judgement and patient preference. For medicines that face NHS access barriers due to NICE decisions, budget constraints, or commissioning restrictions, the private market can represent a significant and faster revenue opportunity. However, most pharma companies have not developed a structured private market access strategy and are missing this channel.
What is the cost of leaving it unaddressed?
No verified UK data available for specific private market penetration revenue generation or market access strategy costs as stated in the problem card. However, the UK private healthcare market is valued at £12.4 billion in 2023, projected to exceed £13.8 billion by 2025 (Petauri, 2025).
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.